Erythema nodosum‐like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients
Michael T. Tetzlaff(The University of Texas MD Anderson Cancer Center), Jonathan L. Curry(The University of Texas MD Anderson Cancer Center), Priyadharsini Nagarajan(The University of Texas MD Anderson Cancer Center), Adrienne N. Choksi(The University of Texas MD Anderson Cancer Center), Phyu P. Aung(The University of Texas MD Anderson Cancer Center), Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Adi Diab(Cleveland Clinic), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Marc Uemura(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Genie A. Landon(The University of Texas MD Anderson Cancer Center), Leon Chen(The University of Texas MD Anderson Cancer Center), Víctor G. Prieto(The University of Texas MD Anderson Cancer Center), Carlos A. Torres‐Cabala(The University of Texas MD Anderson Cancer Center), Brinda Rao Korivi(The University of Texas MD Anderson Cancer Center)
Cited by 59
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739